The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
Leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.
The article offers 6 tips for successful pharma startups.
This case study delves into the company story, technology and vision.
The list looks at how companies are performing and what they are working on.
Technology Networks cover the development, benefits and applications of ioSkeletal Myocytes.
Founder and CEO Dr Mark Kotter joined the experts who have given their thoughts on what is to come for the health sector in 2022.
Wired spoke to bit.bio's CEO and CMO about reprogramming cells for therapies.
The Charles River's Laboratories Disruptor series celebrates the work of their innovative partners.